Aprea Therapeutics (NASDAQ:APRE) Coverage Initiated by Analysts at LADENBURG THALM/SH SH

Research analysts at LADENBURG THALM/SH SH initiated coverage on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note issued to investors on Wednesday, Briefing.com reports. The firm set a “buy” rating and a $2.00 price target on the stock. LADENBURG THALM/SH SH’s target price points to a potential upside of 233.33% from the stock’s current price.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday, July 17th. Wedbush reduced their price target on Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $2.80.

Aprea Therapeutics Stock Up 1.2%

APRE opened at $0.60 on Wednesday. Aprea Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $1.69. The company has a fifty day moving average of $0.73 and a two-hundred day moving average of $0.77.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. Sell-side analysts predict that Aprea Therapeutics will post -0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently raised its stake in Aprea Therapeutics stock. AIGH Capital Management LLC boosted its stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) by 174.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,015,541 shares of the company’s stock after buying an additional 645,000 shares during the quarter. AIGH Capital Management LLC owned approximately 8.47% of Aprea Therapeutics worth $775,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Its research focuses on treatments designed to exploit weaknesses in tumor cells, with an emphasis on DNA damage response and cell-cycle regulation.

The company’s lead investigational program is ATRN-119, an oral, selective inhibitor of ataxia telangiectasia and Rad3-related protein, or ATR. ATRN-119 is being evaluated in early-stage clinical studies for patients with advanced solid tumors.